Adavosertib (AZD1775) has been investigated in numerous clinical trials ranging from early phase I through phase II. These studies evaluate its efficacy in advanced solid neoplasms—including uterine carcinoma, esophageal adenocarcinoma, CCNE1-amplified tumors, and TP53-mutated or resistant ovarian cancer—alongside hematologic malignancies such as acute myeloid leukemia. Sponsored by academic medical centers and industry partners, including the National Cancer Institute, AstraZeneca, Dana-Farber Cancer Institute, and Merck Sharp & Dohme LLC, these protocols encompass active, completed, and terminated statuses.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02813135 | RECRUITING | Pediatric Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2016-08-03 | PHASE1; PHASE2 |
| NCT02659241 | ACTIVE_NOT_RECRUITING | Advanced Fallopian Tube Carcinoma; Advanced Ovarian Carcinoma; Advanced Primary Peritoneal Carcinoma; Carcinomatosis; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v7; Stage III Ovarian Cancer AJCC v6 and v7; Stage III Primary Peritoneal Cancer AJCC v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7 |
M.D. Anderson Cancer Center |
2016-02-04 | EARLY_PHASE1 |
| NCT02465060 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma |
National Cancer Institute (NCI) |
2015-08-17 | PHASE2 |
| NCT03579316 | ACTIVE_NOT_RECRUITING | Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
M.D. Anderson Cancer Center |
2018-12-07 | PHASE2 |
| NCT03284385 | ACTIVE_NOT_RECRUITING | Clear Cell Renal Cell Carcinoma; Locally Advanced Clear Cell Renal Cell Carcinoma; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
National Cancer Institute (NCI) |
2019-01-29 | PHASE2 |
| NCT03385655 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Canadian Cancer Trials Group |
2018-08-01 | PHASE2 |
| NCT04460937 | ACTIVE_NOT_RECRUITING | Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Distal Esophagus Adenocarcinoma; Gastric Cardia Adenocarcinoma; Metastatic Esophageal Adenocarcinoma; Metastatic Esophageal Squamous Cell Carcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Leptomeninges; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Unresectable Esophageal Adenocarcinoma; Unresectable Esophageal Carcinoma; Unresectable Esophageal Squamous Cell Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma |
National Cancer Institute (NCI) |
2021-04-09 | PHASE1 |
| NCT05212025 | WITHDRAWN | Pancreatic Cancer |
James Cleary, MD, PhD |
2022-06 | PHASE2 |
| NCT01164995 | COMPLETED | Epithelial Ovarian Cancer |
The Netherlands Cancer Institute |
2010-07 | PHASE2 |
| NCT04197713 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2020-06-30 | PHASE1 |
| NCT03253679 | COMPLETED | Advanced Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2019-01-16 | PHASE2 |
| NCT04959266 | TERMINATED | Advanced Solid Tumours |
AstraZeneca |
2021-06-28 | PHASE1 |
| NCT04590248 | COMPLETED | Uterine Serous Carcinoma |
AstraZeneca |
2020-11-30 | PHASE2 |
| NCT03345784 | TERMINATED | Cervical Carcinoma; Endometrioid Adenocarcinoma; Malignant Female Reproductive System Neoplasm; Recurrent Cervical Carcinoma; Stage I Uterine Corpus Cancer AJCC v7; Stage I Vaginal Cancer AJCC v6 and v7; Stage IA Uterine Corpus Cancer AJCC v7; Stage IB Cervical Cancer AJCC v6 and v7; Stage IB Uterine Corpus Cancer AJCC v7; Stage IB2 Cervical Cancer AJCC v6 and v7; Stage II Cervical Cancer AJCC v7; Stage II Uterine Corpus Cancer AJCC v7; Stage II Vaginal Cancer AJCC v6 and v7; Stage IIA Cervical Cancer AJCC v7; Stage IIB Cervical Cancer AJCC v6 and v7; Stage III Cervical Cancer AJCC v6 and v7; Stage III Uterine Corpus Cancer AJCC v7; Stage III Vaginal Cancer AJCC v6 and v7; Stage IIIA Cervical Cancer AJCC v6 and v7; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Cervical Cancer AJCC v6 and v7; Stage IIIB Uterine Corpus Cancer AJCC v7; Stage IIIC Uterine Corpus Cancer AJCC v7; Vaginal Carcinoma |
National Cancer Institute (NCI) |
2018-05-29 | PHASE1 |
| NCT04949425 | TERMINATED | Advanced Solid Tumours |
AstraZeneca |
2021-09-13 | PHASE1 |
| NCT02101775 | ACTIVE_NOT_RECRUITING | Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor; Ovarian Mucinous Cystadenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Ovarian Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
National Cancer Institute (NCI) |
2014-07-21 | PHASE2 |
| NCT05008913 | TERMINATED | Advanced Solid Tumors |
AstraZeneca |
2021-10-01 | PHASE1 |
| NCT04462952 | COMPLETED | Advanced Solid Tumours |
AstraZeneca |
2020-06-24 | PHASE1 |
| NCT01849146 | COMPLETED | Glioblastoma; Recurrent Glioblastoma |
National Cancer Institute (NCI) |
2013-10-24 | PHASE1 |
| NCT01827384 | COMPLETED | Advanced Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2014-01-07 | PHASE2 |
| NCT01922076 | COMPLETED | Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant; Glioblastoma; Gliosarcoma |
National Cancer Institute (NCI) |
2013-09-03 | PHASE1 |
| NCT02095132 | COMPLETED | Central Nervous System Embryonal Tumor With Rhabdoid Features; Central Nervous System Embryonal Tumor, Not Otherwise Specified; Central Nervous System Ganglioneuroblastoma; Embryonal Tumor With Multilayered Rosettes, C19MC-Altered; Pineoblastoma; Primary Central Nervous System Neoplasm; Recurrent Childhood Central Nervous System Embryonal Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Rhabdomyosarcoma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Rhabdomyosarcoma |
National Cancer Institute (NCI) |
2014-03-28 | PHASE1; PHASE2 |
| NCT03330847 | ACTIVE_NOT_RECRUITING | Metastatic Triple Negative Breast Cancer |
AstraZeneca |
2018-03-07 | PHASE2 |
| NCT04439227 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2017-03-24 | PHASE2 |
| NCT01748825 | COMPLETED | Solid Tumors |
National Cancer Institute (NCI) |
2012-12-19 | PHASE1 |
| NCT02617277 | COMPLETED | Advanced Solid Tumours |
AstraZeneca |
2015-12-28 | PHASE1 |
| NCT03253679 | Completed | Advanced Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2019-01-16 | Phase 2 |
| NCT02272790 | COMPLETED | Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation |
AstraZeneca |
2015-01-30 | PHASE2 |
| NCT03668340 | Active not recruiting | Uterine Cancer |
Dana-Farber Cancer Institute|AstraZeneca |
2018-10-22 | Phase 2 |
| NCT02037230 | COMPLETED | Adenocarcinoma of the Pancreas |
University of Michigan Rogel Cancer Center |
2014-01 | PHASE1; PHASE2 |
| NCT02381548 | TERMINATED | Acute Myeloid Leukemia; Acute Myeloid Leukemia Post Cytotoxic Therapy; Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive; Refractory Acute Myeloid Leukemia; Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive; Secondary Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2015-08-18 | PHASE1 |
| NCT03028766 | Completed | Hypopharynx Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Larynx Cancer |
University of Birmingham|AstraZeneca|Cancer Research UK |
2017-06-22 | Phase 1 |
| NCT01357161 | COMPLETED | Ovarian Cancer |
Merck Sharp & Dohme LLC |
2011-07-26 | PHASE2 |
| NCT02196168 | TERMINATED | Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Tongue Carcinoma |
National Cancer Institute (NCI) |
2014-03 | PHASE2 |
| NCT00648648 | COMPLETED | Solid Tumors |
Merck Sharp & Dohme LLC |
2008-02-25 | PHASE1 |
| NCT01047007 | TERMINATED | Solid Tumors |
Merck Sharp & Dohme LLC |
2010-01-18 | PHASE1 |
| NCT01076400 | TERMINATED | Cervical Cancer |
Merck Sharp & Dohme LLC |
2010-05-31 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-07-10)
Check the
Adavosertib (AZD1775, MK-1775)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Adavosertib (AZD1775, MK-1775) Mechanism of Action: WEE1 Inhibition in Ovarian Cancer Cell Research
- Adavosertib (AZD1775, MK-1775): Selectivity & Specificity
- Adavosertib (AZD1775, MK-1775) Working Concentration | Cell Culture | Treatment
- Adavosertib (AZD1775, MK-1775) Solubility in DMSO
- Adavosertib (AZD1775, MK-1775) Stock Solution
- Adavosertib (AZD1775, MK-1775) Storage
- Adavosertib (AZD1775, MK-1775) Stability
- Adavosertib (AZD1775, MK-1775) Combination Database
- Adavosertib (AZD1775, MK-1775) Molecular Weight
- Adavosertib (AZD1775, MK-1775) SMILES
- Adavosertib (AZD1775, MK-1775) CAS Number
- Adavosertib (AZD1775, MK-1775) Chemical Structure (2D and 3D)
- Adavosertib (AZD1775, MK-1775) IC50 for Cell-based and Cell-free Assays
- Adavosertib (AZD1775, MK-1775) Sigma (BL3H1F1C7CA8)? Try a better option.
- Adavosertib (AZD1775, MK-1775) MedChemExpress (HY-10993)? Try a better option.
- Adavosertib (AZD1775, MK-1775) Tocris (7589)? Try a better option.
- Adavosertib (AZD1775, MK-1775) CST (69589)? Try a better option.
- Adavosertib (AZD1775, MK-1775) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.